NuCana PLC
NCNA3.560USD
+0.090+2.59%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
5.11BMarket Cap
0.01P/E TTM
More Details of NuCana PLC Company
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
NuCana PLC Info
Ticker SymbolNCNA
Company nameNuCana PLC
IPO dateSep 28, 2017
CEO- -
Number of employees20
Security typeDepository Receipt
Fiscal year-endSep 28
AddressLochside House
CityEDINBURGH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeEH12 9DT
Phone4401313571111
Websitehttps://www.nucana.com/
Ticker SymbolNCNA
IPO dateSep 28, 2017
CEO- -
Company Executives of NuCana PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
+16.67%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
+300.00%
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Ian Webster
Mr. Ian Webster
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
+16.67%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
+300.00%
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 17
Updated: Wed, Dec 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Abingworth Management Limited
1.86%
Glass Jacobson Wealth Advisors
0.21%
Jane Street Capital, L.L.C.
0.18%
UBS Financial Services, Inc.
0.14%
Global Retirement Partners, LLC
0.06%
Other
97.55%
Shareholders
Shareholders
Proportion
Abingworth Management Limited
1.86%
Glass Jacobson Wealth Advisors
0.21%
Jane Street Capital, L.L.C.
0.18%
UBS Financial Services, Inc.
0.14%
Global Retirement Partners, LLC
0.06%
Other
97.55%
Shareholder Types
Shareholders
Proportion
Venture Capital
1.87%
Investment Advisor
0.42%
Research Firm
0.18%
Hedge Fund
0.02%
Other
97.52%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
49
156.10K
8.18%
+152.88K
2025Q2
52
554.99K
0.15%
+48.75K
2025Q1
52
492.36K
2.30%
-26.46K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Abingworth Management Limited
667.00
0.04%
--
--
Jun 30, 2025
Glass Jacobson Wealth Advisors
75.00
0%
--
--
Jun 30, 2025
Sofinnova Investments, Inc
998.00
0.05%
+998.00
--
Feb 14, 2025
Rhumbline Advisers Ltd. Partnership
40.00
0%
+31.00
+344.44%
Jun 30, 2025
Griffith (Hugh S)
53.00
0%
--
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 11, 2025
Merger
200→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Date
Type
Ratio
Jul 11, 2025
Merger
200→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
FAQs
Who are the top five shareholders of NuCana PLC?
The top five shareholders of NuCana PLC are:
Abingworth Management Limited holds 667.00 shares, accounting for 0.04% of the total shares.
Glass Jacobson Wealth Advisors holds 75.00 shares, accounting for 0.00% of the total shares.
Sofinnova Investments, Inc holds 998.00 shares, accounting for 0.05% of the total shares.
Rhumbline Advisers Ltd. Partnership holds 40.00 shares, accounting for 0.00% of the total shares.
Griffith (Hugh S) holds 53.00 shares, accounting for 0.00% of the total shares.
Abingworth Management Limited holds 667.00 shares, accounting for 0.04% of the total shares.
Glass Jacobson Wealth Advisors holds 75.00 shares, accounting for 0.00% of the total shares.
Sofinnova Investments, Inc holds 998.00 shares, accounting for 0.05% of the total shares.
Rhumbline Advisers Ltd. Partnership holds 40.00 shares, accounting for 0.00% of the total shares.
Griffith (Hugh S) holds 53.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of NuCana PLC?
The top three shareholder types of NuCana PLC are:
Abingworth Management Limited
Glass Jacobson Wealth Advisors
Jane Street Capital, L.L.C.
Abingworth Management Limited
Glass Jacobson Wealth Advisors
Jane Street Capital, L.L.C.
How many institutions hold shares of NuCana PLC (NCNA)?
As of 2025Q3, 49 institutions hold shares of NuCana PLC, with a combined market value of approximately 156.10K, accounting for 8.18% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 8.04%.
What is the biggest source of revenue for NuCana PLC?
In --, the -- business generated the highest revenue for NuCana PLC, amounting to -- and accounting for --% of total revenue.
